TY - JOUR AU - Ikeda, H. AU - Lethe, B. AU - Lehmann, F. AU - Baren, N. AU - Baurain, J. F. AU - Smet, C. PY - 1997 DA - 1997// TI - Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor JO - Immunity VL - 6 UR - https://doi.org/10.1016/S1074-7613(00)80426-4 DO - 10.1016/S1074-7613(00)80426-4 ID - Ikeda1997 ER - TY - JOUR AU - Baren, N. AU - Chambost, H. AU - Ferrant, A. AU - Michaux, L. AU - Ikeda, H. AU - Millard, I. PY - 1998 DA - 1998// TI - PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells JO - Br J Haematol VL - 102 UR - https://doi.org/10.1046/j.1365-2141.1998.00982.x DO - 10.1046/j.1365-2141.1998.00982.x ID - Baren1998 ER - TY - JOUR AU - Epping, M. T. AU - Wang, L. AU - Edel, M. J. AU - Carlee, L. AU - Hernandez, M. AU - Bernards, R. PY - 2005 DA - 2005// TI - The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling JO - Cell VL - 122 UR - https://doi.org/10.1016/j.cell.2005.07.003 DO - 10.1016/j.cell.2005.07.003 ID - Epping2005 ER - TY - JOUR AU - Oehler, V. G. AU - Guthrie, K. A. AU - Cummings, C. L. AU - Sabo, K. AU - Wood, B. L. AU - Gooley, T. PY - 2009 DA - 2009// TI - The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2008-07-170282 DO - 10.1182/blood-2008-07-170282 ID - Oehler2009 ER - TY - JOUR AU - Marchand, M. AU - Baren, N. AU - Weynants, P. AU - Brichard, V. AU - Dreno, B. AU - Tessier, M. H. PY - 1999 DA - 1999// TI - Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 JO - Int J Cancer VL - 80 UR - https://doi.org/3.0.CO;2-S DO - 3.0.CO;2-S ID - Marchand1999 ER - TY - JOUR AU - Robbins, P. F. AU - Kassim, S. H. AU - Tran, T. L. AU - Crystal, J. S. AU - Morgan, R. A. AU - Feldman, S. A. PY - 2015 DA - 2015// TI - A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2708 DO - 10.1158/1078-0432.CCR-14-2708 ID - Robbins2015 ER - TY - JOUR AU - Iura, K. AU - Kohashi, K. AU - Hotokebuchi, Y. AU - Ishii, T. AU - Maekawa, A. AU - Yamada, Y. PY - 2015 DA - 2015// TI - Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma JO - J Pathol Clin Res VL - 1 UR - https://doi.org/10.1002/cjp2.16 DO - 10.1002/cjp2.16 ID - Iura2015 ER - TY - JOUR AU - Iura, K. AU - Maekawa, A. AU - Kohashi, K. AU - Ishii, T. AU - Bekki, H. AU - Otsuka, H. PY - 2017 DA - 2017// TI - Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1 JO - Hum Pathol VL - 61 UR - https://doi.org/10.1016/j.humpath.2016.12.006 DO - 10.1016/j.humpath.2016.12.006 ID - Iura2017 ER - TY - JOUR AU - Tan, P. AU - Zou, C. AU - Yong, B. AU - Han, J. AU - Zhang, L. AU - Su, Q. PY - 2012 DA - 2012// TI - Expression and prognostic relevance of PRAME in primary osteosarcoma JO - Biochem Biophys Res Commun VL - 419 UR - https://doi.org/10.1016/j.bbrc.2012.02.110 DO - 10.1016/j.bbrc.2012.02.110 ID - Tan2012 ER - TY - JOUR AU - Pollack, S. M. AU - Li, Y. AU - Blaisdell, M. J. AU - Farrar, E. A. AU - Chou, J. AU - Hoch, B. L. PY - 2012 DA - 2012// TI - NYESO-1/LAGE-1 s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine JO - PLoS ONE VL - 7 UR - https://doi.org/10.1371/journal.pone.0032165 DO - 10.1371/journal.pone.0032165 ID - Pollack2012 ER - TY - JOUR PY - 2013 DA - 2013// TI - The genotype-tissue expression (GTEx) project JO - Nat Genet VL - 45 UR - https://doi.org/10.1038/ng.2653 DO - 10.1038/ng.2653 ID - ref11 ER - TY - JOUR AU - Barretina, J. AU - Caponigro, G. AU - Stransky, N. AU - Venkatesan, K. AU - Margolin, A. A. AU - Kim, S. PY - 2012 DA - 2012// TI - The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity JO - Nature VL - 483 UR - https://doi.org/10.1038/nature11003 DO - 10.1038/nature11003 ID - Barretina2012 ER - TY - JOUR AU - Wagner, G. P. AU - Kin, K. AU - Lynch, V. J. PY - 2012 DA - 2012// TI - Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples JO - Theory Biosci VL - 131 UR - https://doi.org/10.1007/s12064-012-0162-3 DO - 10.1007/s12064-012-0162-3 ID - Wagner2012 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2016 DA - 2016// TI - Cancer statistics, 2016 JO - CA Cancer J Clin VL - 66 UR - https://doi.org/10.3322/caac.21332 DO - 10.3322/caac.21332 ID - Siegel2016 ER - TY - JOUR AU - Ratan, R. AU - Patel, S. R. PY - 2016 DA - 2016// TI - Chemotherapy for soft tissue sarcoma JO - Cancer VL - 122 UR - https://doi.org/10.1002/cncr.30191 DO - 10.1002/cncr.30191 ID - Ratan2016 ER - TY - STD TI - Tawbi HA, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetze S, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): results of SARC028—a multicenter phase II study. J Clin Oncol 2016; 34(suppl; abstr 11006). ID - ref16 ER - TY - JOUR AU - Resnick, M. B. AU - Sabo, E. AU - Kondratev, S. AU - Kerner, H. AU - Spagnoli, G. C. AU - Yakirevich, E. PY - 2002 DA - 2002// TI - Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas JO - Int J Cancer VL - 101 UR - https://doi.org/10.1002/ijc.10585 DO - 10.1002/ijc.10585 ID - Resnick2002 ER - TY - JOUR AU - Mitsis, D. AU - Francescutti, V. AU - Skitzki, J. PY - 2016 DA - 2016// TI - Current immunotherapies for sarcoma: clinical trials and rationale JO - Sarcoma VL - 2016 UR - https://doi.org/10.1155/2016/9757219 DO - 10.1155/2016/9757219 ID - Mitsis2016 ER - TY - JOUR AU - Garrido, F. AU - Aptsiauri, N. AU - Doorduijn, E. M. AU - Garcia Lora, A. M. AU - Hall, T. PY - 2016 DA - 2016// TI - The urgent need to recover MHC class I in cancers for effective immunotherapy JO - Curr Opin Immunol VL - 39 UR - https://doi.org/10.1016/j.coi.2015.12.007 DO - 10.1016/j.coi.2015.12.007 ID - Garrido2016 ER -